Todays Report: Today, Valeant Pharmaceuticals International Inc. (VRX) Rating Reiterated by Mizuho

Today, Valeant Pharmaceuticals International Inc. (VRX) Rating Reiterated by Mizuho

Valeant Pharmaceuticals International Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Mizuho in a research note issued to investors on Saturday. They currently have a $25.00 target price on the specialty pharmaceutical company’s stock. Mizuho’s price objective suggests a potential upside of 47.06% from the company’s previous close.

VRX has been the subject of several other research reports. Deutsche Bank AG decreased their target price on Valeant Pharmaceuticals International from $30.00 to $29.00 and set a “hold” rating for the company in a research note on Friday, October 14th. Wells Fargo & Co. reaffirmed an “underperform” rating and set a $19.50 target price on shares of Valeant Pharmaceuticals International in a research note on Tuesday, October 18th. Morgan Stanley reaffirmed a “positive” rating on shares of Valeant Pharmaceuticals International in a research note on Friday, August 19th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, October 25th. Finally, RBC Capital Markets set a $36.00 target price on Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Friday, August 19th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Valeant Pharmaceuticals International presently has an average rating of “Hold” and an average price target of $39.63.

Valeant Pharmaceuticals International (NYSE:VRX) traded up 0.35% during mid-day trading on Friday, reaching $17.00. The company’s stock had a trading volume of 8,772,323 shares. Valeant Pharmaceuticals International has a 1-year low of $13.77 and a 1-year high of $119.87. The firm’s market capitalization is $5.91 billion. The firm has a 50-day moving average of $20.02 and a 200 day moving average of $24.13.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.78 by $0.23. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 43.81%. The firm had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.49 billion. During the same period in the prior year, the business earned $2.74 EPS. The company’s quarterly revenue was down 11.0% compared to the same quarter last year. Equities analysts expect that Valeant Pharmaceuticals International will post $5.43 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of VRX. LPL Financial LLC increased its position in Valeant Pharmaceuticals International by 65.5% in the first quarter. LPL Financial LLC now owns 91,050 shares of the specialty pharmaceutical company’s stock valued at $2,616,000 after buying an additional 36,046 shares during the period. Seven Eight Capital LLC bought a new position in Valeant Pharmaceuticals International during the first quarter valued at approximately $374,000. Boothbay Fund Management LLC increased its position in Valeant Pharmaceuticals International by 275.4% in the first quarter. Boothbay Fund Management LLC now owns 7,632 shares of the specialty pharmaceutical company’s stock valued at $201,000 after buying an additional 5,599 shares during the period. BNP Paribas Arbitrage SA increased its position in Valeant Pharmaceuticals International by 18.6% in the second quarter. BNP Paribas Arbitrage SA now owns 434,323 shares of the specialty pharmaceutical company’s stock valued at $8,747,000 after buying an additional 68,267 shares during the period. Finally, Cacti Asset Management LLC increased its position in Valeant Pharmaceuticals International by 68.0% in the second quarter. Cacti Asset Management LLC now owns 8,400 shares of the specialty pharmaceutical company’s stock valued at $169,000 after buying an additional 3,400 shares during the period. Institutional investors and hedge funds own 67.13% of the company’s stock.

About Valeant Pharmaceuticals International

Related posts

Leave a Comment